Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:40:31 EDT Sat 05 Sep 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:NVCR from 2025-09-05 to 2026-09-04 - 23 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-09-02 07:00U:NVCRNews ReleaseNovocure Announces Upcoming Investor Events
2026-07-23 07:00U:NVCRNews ReleaseNovocure Reports Second Quarter 2026 Financial Results
2026-07-01 07:00U:NVCRNews ReleaseNovocure to Report Second Quarter 2026 Financial Results
2026-06-30 07:00U:NVCRNews ReleaseNovocure's Optune Pax(TM) Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
2026-06-18 07:00U:NVCRNews ReleaseNovocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
2026-04-30 07:00U:NVCRNews ReleaseNovocure Reports First Quarter 2026 Financial Results
2026-04-01 07:00U:NVCRNews ReleaseNovocure to Report First Quarter 2026 Financial Results
2026-03-26 07:00U:NVCRNews ReleaseNovocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
2026-03-02 07:00U:NVCRNews ReleaseNovocure Announces Optune Lua(TM) Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
2026-02-27 16:30U:NVCRNews ReleaseNovocure to Participate in 2026 Leerink Global Healthcare Conference
2026-02-26 07:00U:NVCRNews ReleaseNovocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
2026-02-24 07:00U:NVCRNews ReleaseTumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
2026-02-11 17:54U:NVCRNews ReleaseU.S. FDA Approves Novocure's Optune Pax(TM) for the Treatment of Locally Advanced Pancreatic Cancer
2026-01-12 07:00U:NVCRNews ReleaseNovocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
2025-12-22 07:00U:NVCRNews ReleaseNovocure to Present at 44th Annual J.P. Morgan Healthcare Conference
2025-12-01 07:00U:NVCRNews ReleaseNovocure Appoints Company President Frank Leonard as Chief Executive Officer
2025-11-26 07:00U:NVCRNews ReleaseNovocure to Participate in 37th Annual Piper Sandler Healthcare Conference
2025-11-12 07:00U:NVCRNews ReleaseNovocure to Participate in 2025 Jefferies Global Healthcare Conference
2025-10-30 07:00U:NVCRNews ReleaseNovocure Reports Third Quarter 2025 Financial Results
2025-10-15 07:00U:NVCRNews ReleaseNovocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
2025-10-01 07:00U:NVCRNews ReleaseNovocure to Report Third Quarter 2025 Financial Results
2025-09-29 16:30U:NVCRNews ReleaseNovocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
2025-09-15 07:00U:NVCRNews ReleaseNovocure's Optune Lua(TM) Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)